Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a study titled ‘Treating Atopic Dermatitis With Abrocitinib and Its Impact in Real Life: An Observational Cohort Study To Describe the Effectiveness of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis.’ The study aims to assess the safety and effectiveness of Abrocitinib in treating adults with moderate to severe atopic dermatitis, a chronic skin condition characterized by inflammation and irritation.
The intervention being tested is Abrocitinib, a drug administered as a daily tablet, designed to alleviate symptoms of atopic dermatitis. Participants can also use medicated topical treatments alongside Abrocitinib.
This is an observational cohort study with a prospective time perspective. All participants will receive the treatment, and the study’s primary purpose is to evaluate real-world outcomes of the drug.
The study began on March 9, 2023, and is currently recruiting participants. The last update was submitted on July 7, 2025, indicating ongoing data collection and analysis.
Pfizer’s study could influence its stock performance positively if results demonstrate significant benefits, as it would strengthen its dermatology portfolio. Investors should monitor competitor activities and market trends in dermatological treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.